In this episode, Thomas Seyfried, a cancer researcher and professor of biology at Boston College, discusses a controversial view of cancer as a mitochondrial metabolic disease. Many topics related to the causes, treatments, and prevention of cancer are covered in this in-depth conversation.

We discuss:

How Tom got interested in cancer research [9:00];
Calorie-restricted ketogenic diets, fasting, and epileptic seizures [18:30];
Otto Warburg and the Warburg effect [30:45];
Germline mutations, somatic mutations, and no mutations [42:00];
Mitochondrial substrate level phosphorylation: Warburg's missing link [51:30];
What is the structural defect in the mitochondria in cancer? [1:02:00];
Peter's near-death experience with the insulin suppression test while in ketosis [1:06:30];
Insulin potentiation therapy and glutamine inhibition [1:13:15];
The macrophage fusion-hybrid theory of metastasis [1:39:30];
How are cancer cells growth dysregulated without a mutation? [1:47:00];
What is the dream clinical trial to test the hypothesis that we can reduce the death rates of cancer by 50%? [2:03:15];
How can the hypothesis be tested rigorously that structural abnormalities in the mitochondria impair respiration and lead to compensatory fermentation? [2:26:30];
Case studies of GBM survivors [2:32:45]; and
More.

Learn more at www.PeterAttiaMD.com

Connect with Peter on Facebook | Twitter | Instagram.

#30 - Thomas Seyfried, Ph.D.: Controversial discussion—cancer as a mitochondrial metabolic disease?